孟鲁司特预防过敏性紫癜肾损害的临床效果观察

中国临床药理学与治疗学 ›› 2014, Vol. 19 ›› Issue (7): 805-808.

孟鲁司特预防过敏性紫癜肾损害的临床效果观察

陈素哲¹, 周耀铃²

¹ 河北省定州市人民医院儿科,定州 073000,河北;
² 北京市昌平区中西医结合医院儿科, 北京 102208

收稿日期:2014-03-27 修回日期:2014-07-01 发布日期:2014-07-21
作者简介:陈素哲,女,本科,主治医师,研究方向:儿童肾脏疾病。 Tel: 15512230710 E-mail: chensuzhe@126.com

Clinical observation of montelukast in prevention of Henoch-Schonlein purpura with renal impairment

CHEN Su-zhe¹, ZHOU Yao-lin²

¹ Department of Pediatrics,People's Hospital of Dingzhou, Dingzhou 073000, Hebei, China;
² Department of Pediatrics,Beijing Changping Area Cooperation of Chinese and Western Medicine Hospital,Beijing 102208,China

Received:2014-03-27 Revised:2014-07-01 Published:2014-07-21

摘要/Abstract

摘要： 目的探讨孟鲁司特防治过敏性紫癜肾损害的临床有效性和安全性。方法采用随机对照方法,将200例过敏性紫癜患儿分为实验组(100 例)和对照组(100 例),两组患儿均给予常规治疗,实验组采用孟鲁司特进行治疗,对照组采用低分子肝素钙进行治疗,观察两组临床治疗效果及不同时间段微量白蛋白、尿 β₂微球蛋白变化。结果实验组有效率为 91.00%,明显高于对照组的 81.00%(χ²= 4.15,P<0.05)。实验组儿童皮疹消失时间、腹痛和关节疼痛缓解时间以及总病程均明显短于对照组(P<0.01)。治疗后实验组尿微量白蛋白、尿β₂微球蛋白水平明显低于对照组 (P<0.01)。结论孟鲁司特预防过敏性紫癜肾损害方法简单,安全可靠,值得临床推广应用。

关键词: 孟鲁司特, 过敏性紫癜, 过敏性紫癜肾炎

Abstract: AIM: To observe the clinical efficacy and safety of montelukast in prevention of Henoch-Schonlein purpura with renal impairment. METHODS: Using a randomized controlled method, 200 cases of Henoch-Schonlein syndrome were randomly divided into the experimental group (n=100)and control group (n=100),two groups were given conventional treatment,the experimental group was based on combined with montelukast and the control group was based on combined with low molecular heparin sodium.The clinical treatment result,the changes of urine albumin and β₂ microglobulin levels in different time periods were observed.RESULTS:Efficacy of the experimental group was 91.00% while the control group was 81.00% (χ²=4.15, P<0.05) .Compared with the control group,the children disappearing time rash, abdominal pain and joint pain remission time and the total duration in the experimental group were significantly shorter (P<0.01). After treatment, the levels of urinary albumin and urinary β₂ microglobulin in experimental group were significantly lower than those in the control group (P<0.01). CONCLUSION: The preventive effect of montelukast on henoch-schonlein purpura with renal involvement method is simple,safe,so it deserves preference in clinic.

Key words: montelukast, henoch-schonlein purpura, henoch-schonlein purpura nephritis

中图分类号:

R729

陈素哲, 周耀铃. 孟鲁司特预防过敏性紫癜肾损害的临床效果观察[J]. 中国临床药理学与治疗学, 2014, 19(7): 805-808.

CHEN Su-zhe, ZHOU Yao-lin. Clinical observation of montelukast in prevention of Henoch-Schonlein purpura with renal impairment[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2014, 19(7): 805-808.

参考文献

[1] Ru L, Abudouhaer A, Guo YF.Clinical significance of serum levels of IGF-1 and IGFBP-3 in children with Henoch-Schonlein purpura or Henoch-Schonlein purpura nephritis[J] .Zhongguo Dang Dai Er Ke Za Zhi,2013,15(11):1009-1013.
[2] Huang D, Wu X, Zheng W, et al.Podocalyxin expression in renal tissues and correlation with the number of urinary podocytes in children with Henoch-Schonlein purpura nephritis[J].Zhong Nan Da Xue Xue Bao Yi Xue Ban,2012,37(2):161-167.
[3] 中华医学会儿科学分会肾脏病学组.紫癜性肾炎的诊断与治疗(草案)[J].中国实用儿科杂志,2003,18:189.
[4] 胡晓燕. 孟鲁司特钠治疗儿童过敏性紫曩临床分析[J].实用医学杂志,2011,27(12):2235-2236.
[5] De Almeida JL, Campos LM, Paim LB,et al.Renal involvementin Henoch-Schonlein purpura: a multivariate analysis of initialprognostic factors[J].J Pediatr (RioJ), 2007, 83(3):259-266.
[6] 方湘玲,易着文,党西强,等.儿童过敏性紫癜 236 例临床分析[J].临床儿科杂 2006, 24(1):46-49.
[7] Borawski J, Naumnik B, Pawlak K, et al.Soluble thrombomodulin is associated with viral hepatitis, blood pressure, and medications in haemodialysis patients[J]. Nephrol Dial Transplant,2001,16(4):787-792.
[8] Huber AM, King J, McLaine P, et al. A randomized, placebo-controllde trial of prednisone in early Henoch-Schonlein purpura[J]. BMC Med, 2004,2(1):7.
[9] 廖培元,吴升华.过敏性紫癜患儿血清白三烯B4、白介素5的测定及临床意义[J].中国当代儿科杂志,2006,8(3):198-200.
[10] 马陆,郭晓渊,皮文霞.孟鲁司特钠治疗婴幼儿非特应性喘息症的疗效分析[J]. 中国临床药理学与治疗学,2011,16(11): 1300-1303.
[11] 李建新,申军.孟鲁司特治疗过敏性紫癜的疗效分析[J].临床与实验医学杂志,2010,9(10) : 61-62.
[12] 王秀萍,曹雪梅,李锋同.孟鲁司特钠治疗过敏性紫癜36例[J].陕西医学杂志,2012,41(5) : 599-601.
[13] 郁颖伶. 孟鲁司特治疗过敏性紫癜 30例临床分析[J].南通大学学报: 医学版,2010,30(6) : 465-466.
[14] 鲁迎. 孟鲁司特治疗过敏性紫癜临床观察[J].临床合理用药,2012,5(1) : 61-62.
[15] Reinhold SW,vitzthum H,Filbeck T,et al.Gene expression of 5-, 12-, and 15-lipoxygenases andleukotriene receptors along the rat nephron[J].Am J Physiol Renal Physiol,2006,290(4):864-872.
[16] Kurogi Y.Mesangial cell proliferation inhibitors for the treatmentof proliferative glomerular disease[J].Med Res Rev,2003,23(1):15-31.